Etravirine (Intelence) Approved for HIV Treatment

The Food and Drug Administration (FDA) has approved a new HIV drug recommended as an adjunct therapy for patients who did not respond to other treatment regimens. Etravirine (Intelence) belongs to a new class of anti-HIV drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTI).

Findings of two clinical trials showed that a combination of darunavir (Prezista) and etravirine (Intelence) was associated with higher percentage of patients reaching undetectable levels of HIV, than a single darunavir (Prezista) therapy. A total of 599 individuals participated in these randomized, double-blind, placebo-controlled trials. Read more